United States Leads Global CRISPR Gene Editing Trials with 356 Studies Underway
The United States is at the forefront of CRISPR gene editing research, leading globally in the number of clinical trials. According to the CMN Clinical Trials Q3 2026 Global Report, there are 356 gene-editing trials worldwide as of September 30, 2026. The U.S. and China collectively account for the majority of these trials, with other significant contributions from Australia, the United Kingdom, Canada, and New Zealand. This report, compiled by CMN Intelligence, utilizes a manually curated global database of clinical gene-editing trials to provide a comprehensive overview of the landscape. The data also delves into various aspects of these trials, including editing approaches, cell sources, and delivery technologies being employed across the global clinical gene-editing landscape. This robust activity signifies a rapid advancement in the application of gene-editing technologies for therapeutic purposes.